Zachary Bessette

Zachary Bessette

Articles by Zachary Bessette

Zachary BessetteRLT | June 11, 2024
A phase 3 trial offers the first randomized evidence of the benefit of PSMA tandem therapy in patients with mCRPC.
Read More
Zachary BessetteProstate Cancer Diagnostics | June 11, 2024
New research provides evidence of 18F-rhPSMA-7 leading to more favorable disease outcomes for patients with BCR after RP.
Zachary BessetteCRPC | June 4, 2024
Dr. Mark David Linch presented the results of NEPTUNES: a multicenter, 2-cohot, biomarker-selected, phase 2 trial.
Zachary BessetteCRPC | June 3, 2024
Results from the CHAARTED2 trial was presented by Dr. Kyriakopoulos of the University of Wisconsin Carbone Cancer Center.
Zachary BessetteMuscle Invasive Urothelial Carcinoma | June 1, 2024
Neoadjuvant SG shows promising clinical activity in patients with MIBC and may help avoid radical cystectomy.
Zachary BessetteTesticular, Penile, and Rare Malignancies | May 31, 2024
A recent trial provides the first evidence of efficacy from ICIs in PSCC with a manageable safety profile.
Zachary BessetteAdvanced Urothelial Carcinoma | May 31, 2024
An update on clinical efficacy and an exploratory biomarker analysis from the NABUCCO trial for patients with stage III UC.
Zachary BessetteAdvanced Renal Cell Carcinoma | June 10, 2024
Patients with RCC who experience disease recurrence after adjuvant IO benefit from subsequent systemic therapies.
Zachary BessetteTesticular, Penile, and Rare Malignancies | May 31, 2024
The SWENOTECA cancer care program sought to evaluate survival, toxicity in patients treated with HDCT from 2011 through 2021.
Zachary BessetteLocalized | May 31, 2024
Researchers attempted to confirm whether treatment suspension for EMBARK patients may lead to improvements in HRQOL.
Zachary BessetteAdvanced Urothelial Carcinoma | May 30, 2024
Dr. van der Heijden presents a follow-up analysis of patients who were cisplatin-ineligible at randomization for EV-302.
Zachary BessetteAdvanced Urothelial Carcinoma | May 29, 2024
A retrospective analysis of ctDNA data by clinical outcomes with pembro vs chemotherapy for aUC from KEYNOTE-361.
Zachary BessettenccRCC | June 7, 2024
Dr. Doshi and colleagues designed an analysis of patients with metastatic ChRCC to better understand first-line therapy.
Zachary BessetteLocalized | May 6, 2024
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Zachary BessetteTesticular, Penile, and Rare Malignancies | May 6, 2024
A study to determine the potential utility of ADCs targeting TROP-2 in both localized PSCC and distant metastases.
Zachary BessetteUpper Tract Urothelial Carcinoma | May 21, 2024
For patients with clinical node-positive UTUC, NAC may lead to improved outcomes compared with adjuvant chemotherapy.
Zachary BessetteAdvanced Renal Cell Carcinoma | May 4, 2024
ICIs improves OS for patients with mRCC and sarcomatoid features who undergo CN, regardless of the timing of surgery.
Zachary BessetteMuscle Invasive Urothelial Carcinoma | May 3, 2024
RT to recurrence sites may not have an effect on oncologic outcomes in patients with MIBC after RC.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | May 3, 2024
A phase 2 clinical trial assessed combination intravesical gemcitabine and docetaxel for BCG-naïve NMIBC.
Zachary BessetteMuscle Invasive Urothelial Carcinoma | May 3, 2024
Identifying tumor biomarkers associated with pCR to neoadjuvant pembro or NAC prior to cystectomy in patients with MIBC.